[go: up one dir, main page]

WO1997005870A3 - Emploi de griseofulvine pour inhiber la croissance des cancers - Google Patents

Emploi de griseofulvine pour inhiber la croissance des cancers Download PDF

Info

Publication number
WO1997005870A3
WO1997005870A3 PCT/US1996/012475 US9612475W WO9705870A3 WO 1997005870 A3 WO1997005870 A3 WO 1997005870A3 US 9612475 W US9612475 W US 9612475W WO 9705870 A3 WO9705870 A3 WO 9705870A3
Authority
WO
WIPO (PCT)
Prior art keywords
griseofulvin
cancers
inhibiting
growth
conjunction
Prior art date
Application number
PCT/US1996/012475
Other languages
English (en)
Other versions
WO1997005870A2 (fr
Inventor
James Berger Camden
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL13301499A priority Critical patent/IL133014A0/xx
Priority to MX9800945A priority patent/MX9800945A/es
Priority to HU9903506A priority patent/HUP9903506A3/hu
Priority to SK142-98A priority patent/SK14298A3/sk
Priority to BR9609920A priority patent/BR9609920A/pt
Priority to JP9508495A priority patent/JPH11511136A/ja
Application filed by Procter & Gamble filed Critical Procter & Gamble
Priority to EP96926807A priority patent/EP0841914A2/fr
Priority to IL12309496A priority patent/IL123094A0/xx
Priority to AU66834/96A priority patent/AU713031B2/en
Publication of WO1997005870A2 publication Critical patent/WO1997005870A2/fr
Publication of WO1997005870A3 publication Critical patent/WO1997005870A3/fr
Priority to NO980420A priority patent/NO980420L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)

Abstract

L'invention concerne une composition pharmaceutique pour le traitement de cancers ou de tumeurs chez les mammifères. Cette composition contient de la griséofulvine. On peut utiliser un agent chimiothérapeutique en association avec la griséofulvine, de même que des agents de potentialisation. La griséofulvine peut également être utilisée pour traiter des infections virales, seule, en association avec d'autres agents antiviraux ou avec un agent de potentialisation.
PCT/US1996/012475 1995-08-03 1996-07-30 Emploi de griseofulvine pour inhiber la croissance des cancers WO1997005870A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
MX9800945A MX9800945A (es) 1995-08-03 1996-07-30 Uso de griseofulvina para inhibir el crecimiento de canceres.
HU9903506A HUP9903506A3 (en) 1995-08-03 1996-07-30 Use of griseofulvin for inhibiting the growth of cancers
SK142-98A SK14298A3 (en) 1995-08-03 1996-07-30 Use of griseofulvin for inhibiting the growth of cancers
BR9609920A BR9609920A (pt) 1995-08-03 1996-07-30 Uso de griseofulvina para inibir o crescimento de cânceres
JP9508495A JPH11511136A (ja) 1995-08-03 1996-07-30 癌の成長を阻害するためのグリセオフルビンの使用
IL13301499A IL133014A0 (en) 1995-08-03 1996-07-30 Pharmaceutical compositions containing griseofulvin for treating viral infections
EP96926807A EP0841914A2 (fr) 1995-08-03 1996-07-30 Emploi de griseofulvine pour inhiber la croissance des cancers
IL12309496A IL123094A0 (en) 1995-08-03 1996-07-30 Pharmaceutical compositions containing griseofulvin for inhibiting the growth of cancers
AU66834/96A AU713031B2 (en) 1995-08-03 1996-07-30 Use of griseofulvin for inhibiting the growth of cancers
NO980420A NO980420L (no) 1995-08-03 1998-01-30 Anvendelse av griseofulvin for å inhibere cancervekst

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US183995P 1995-08-03 1995-08-03
US60/001,839 1995-08-03
US67418196A 1996-07-16 1996-07-16
US08/674,181 1996-07-16

Publications (2)

Publication Number Publication Date
WO1997005870A2 WO1997005870A2 (fr) 1997-02-20
WO1997005870A3 true WO1997005870A3 (fr) 1997-04-17

Family

ID=26669547

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/012475 WO1997005870A2 (fr) 1995-08-03 1996-07-30 Emploi de griseofulvine pour inhiber la croissance des cancers

Country Status (16)

Country Link
EP (1) EP0841914A2 (fr)
JP (1) JPH11511136A (fr)
KR (1) KR19990036137A (fr)
AR (1) AR003176A1 (fr)
AU (1) AU713031B2 (fr)
BR (1) BR9609920A (fr)
CA (1) CA2228503A1 (fr)
CZ (1) CZ30598A3 (fr)
HU (1) HUP9903506A3 (fr)
IL (1) IL123094A0 (fr)
MX (1) MX9800945A (fr)
NO (1) NO980420L (fr)
PL (1) PL324905A1 (fr)
SK (1) SK14298A3 (fr)
TR (1) TR199800244T2 (fr)
WO (1) WO1997005870A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6930121B2 (en) 2000-09-26 2005-08-16 Uaf Technologies And Research, Llc Compounds and methods for use thereof in the treatment of viral infections

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
WO2000006143A1 (fr) * 1998-07-27 2000-02-10 Texas Pharmaceuticals, Inc. Hyperthermie intracellulaire induite chimiquement
US7682612B1 (en) * 1998-11-09 2010-03-23 Biogen Idec Inc. Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6407105B1 (en) 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
EP1407784B1 (fr) * 2001-06-25 2010-11-24 Ajinomoto Co., Inc. Agents antitumoraux
EP2008652A1 (fr) * 2007-06-28 2008-12-31 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Analogues de la griséofulvine pour le traitement du cancer par inhibition du regroupement centrosomal
EP2204367A1 (fr) * 2008-12-22 2010-07-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Analogues de la griséofulvine pour le traitement du cancer par inhibition du regroupement centrosomal

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
E. HUANT: "Premières expérimentations cliniques de l'activité anti-mitotique de la griséofulvine en thérapeutique antitumorale.", THERAPIE, vol. 22, no. 5, 1967, pages 1143 - 1151, XP000617126 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6930121B2 (en) 2000-09-26 2005-08-16 Uaf Technologies And Research, Llc Compounds and methods for use thereof in the treatment of viral infections

Also Published As

Publication number Publication date
AR003176A1 (es) 1998-07-08
TR199800244T2 (xx) 1998-09-21
JPH11511136A (ja) 1999-09-28
CZ30598A3 (cs) 1998-06-17
PL324905A1 (en) 1998-06-22
SK14298A3 (en) 1998-09-09
HUP9903506A3 (en) 2000-07-28
HUP9903506A2 (hu) 2000-06-28
AU6683496A (en) 1997-03-05
EP0841914A2 (fr) 1998-05-20
MX9800945A (es) 1998-04-30
BR9609920A (pt) 1999-07-06
CA2228503A1 (fr) 1997-02-20
IL123094A0 (en) 1998-09-24
WO1997005870A2 (fr) 1997-02-20
NO980420D0 (no) 1998-01-30
AU713031B2 (en) 1999-11-18
KR19990036137A (ko) 1999-05-25
NO980420L (no) 1998-04-03

Similar Documents

Publication Publication Date Title
WO1997005870A3 (fr) Emploi de griseofulvine pour inhiber la croissance des cancers
WO2001016136A3 (fr) Inhibiteurs tricycliques de poly(adp-ribose) polymerases
WO2001024763A3 (fr) Compositions et methodes de traitement du cancer utilisant des immunoconjugues et des agents chimiotherapeutiques
WO1999054326A8 (fr) Dihydropyrimidines
AU6276194A (en) Use of monoterpenes, sesquiterpernes and diterpernes for the treatment of cancer
MY122771A (en) Heterocyclically substituted benzimidazoles, their preparation and use thereof
EP2289940A3 (fr) Traitement de maladie métastatique
CA2292359A1 (fr) Nouveaux azalides et procede de fabrication
NZ507350A (en) Semi-synthetic ecteinascidins and use in treatment of tumors
AU1392900A (en) 2,5-diazabicyclo(2.2.1)heptane derivatives, their preparation and therapeutic uses
WO1997005873A3 (fr) Utilisation de fluconazole pour inhiber la croissance de cancers
WO1993000094A3 (fr) Utilisation de derives de tetrahydrobenzazepine pour le traitement de l'hypertension porte et de la migraine
WO1997004788A3 (fr) Utilisation de glycosides de calendula dans le traitement du psoriasis
HK1050132A1 (zh) 治疗癌症的溶瘤配方
WO1997005872A3 (fr) Emploi de derives de 1h-1,2,4-triazole pour inhiber la croissance de cancers
WO1999061010A3 (fr) TRAITEMENT DE L'INFERTILITE PAR DES COMPOSES STIMULANT LA PRODUCTION D'AMPc, SEULS OU ASSOCIES A AU MOINS UN COMPOSE STIMULANT LA MEIOSE
IE881410L (en) Anticoccidial composition
AU4985596A (en) Novel aroylaniline derivatives, compositions and uses thereof in the treatment of viral infections
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
WO2001046178A3 (fr) Pyrroles substitues
AU3600199A (en) A pharmaceutical composition containing ezrin mutated on tyrosine 353
AU2566101A (en) Compounds and methods for the treatment of pain
CA2410160A1 (fr) Polytherapie anticancereuse a base de derives de distamycine a substitution acryloyle et d'agents alkylants
WO2001022917A3 (fr) Compositions effervescentes comportant du nimesulide
AU1595101A (en) Oncolytic combinations for the treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2228503

Country of ref document: CA

Ref document number: 2228503

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV1998-305

Country of ref document: CZ

Ref document number: 14298

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 1997 508495

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1998/000945

Country of ref document: MX

Ref document number: 1019980700805

Country of ref document: KR

Ref document number: 315185

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1996926807

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1199800130

Country of ref document: VN

WWE Wipo information: entry into national phase

Ref document number: 1998/00244

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 1996926807

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1998-305

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019980700805

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2000 2000705213

Country of ref document: KR

Kind code of ref document: A

WWW Wipo information: withdrawn in national office

Ref document number: 1996926807

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1019980700805

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV1998-305

Country of ref document: CZ